Alzheimer's Research & Therapy | Volume 2 Issue 2

Advanced search

Submit a manuscript Register

Explore journal

Articles

cover

	Volume 2 Issue 2
	Comment
	Commentary Pinpointing key mechanisms in Alzheimer's disease development Julie Williams Alzheimer's Research & Therapy 2010, 2:4 (31 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Williams comments on a recent study implicating inflammation and innate immunity in Alzheimer’s disease development, discussing these results in the context of recent genetic studies on the disease.
	Commentary Can novel therapeutics halt the amyloid cascade? Niels D Prins, Pieter Visser, Philip Scheltens Alzheimer's Research & Therapy 2010, 2:5 (9 April 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Prins and colleagues discuss the negative results of the recent bapineuzumab and tarenflurbil trials, the lessons learnt from them and comment on the potential implications for future novel therapeutics.
	Commentary Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander? Zaldy S Tan, Sudha Seshadri Alzheimer's Research & Therapy 2010, 2:6 (12 April 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Tan and Seshadri consider evidence linking inflammation to Alzheimer’s disease risk, discussing the growing body of evidence that suggests inflammatory biomarkers could be used to risk-stratify people for preventative/therapeutic interventions.
	Commentary Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease? Kaj Blennow, Henrik Zetterberg Alzheimer's Research & Therapy 2010, 2:8 (30 April 2010) Abstract \| Full text \| PDF \| PubMed
	Viewpoint Con: Can neuropathology really confirm the exact diagnosis? Kurt A Jellinger Alzheimer's Research & Therapy 2010, 2:11 (7 May 2010) Abstract \| Full text \| PDF \| PubMed \| 1 comment \| Editor’s summary Jellinger comments on the drawbacks of neuropathology as a diagnostic tool for Alzheimer’s disease and argues that to improve the accuracy and reproducibility of its diagnosis, we should be using harmonized techniques.
	Viewpoint Pro: Can neuropathology really confirm the exact diagnosis? Margaret M Esiri Alzheimer's Research & Therapy 2010, 2:10 (7 May 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Esiri discusses the benefits of neuropathology as a diagnostic tool for Alzheimer’s disease, arguing that it still holds the key to revealing the complex molecular and cellular mechanisms of the disease.
	Research
	Research A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease Erik Portelius, Robert A Dean, Mikael K Gustavsson, Ulf Andreasson, Henrik Zetterberg, Eric Siemers, Kaj Blennow Alzheimer's Research & Therapy 2010, 2:7 (29 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Amyloid beta isoforms in cerebrospinal fluid increase during gamma-secretase inhibitor treatment in Alzheimer's disease (AD), and may be used as novel sensitive biomarkers to monitor the biochemical effect in clinical trials.